

**Figure 1. Recommended immunization schedule for persons aged 0 through 18 years – United States, 2016.**

**(FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]).**

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded.

| Vaccine   | Birth                | 1 mo                             | 2 mos                | 4 mos                            | 6 mos                                      | 9 mos                                      | 12 mos | 15 mos | 18 mos  | 19–23 mos | 2–3 yrs                                       | 4–6 yrs              | 7–10 yrs                                     | 11–12 yrs            | 13–15 yrs | 16–18 yrs |
|---|----------------------|----------------------------------|----------------------|----------------------------------|--|--|--------|--------|---|-----------|---|----------------------|--|----------------------|-----------|-----------|
| Hepatitis B <sup>1</sup> (HepB)   | 1 <sup>st</sup> dose | ←-----2 <sup>nd</sup> dose-----→ |                      | ←-----3 <sup>rd</sup> dose-----→ |  |  |        |        |   |           |   |                      |  |                      |           |           |
| Rotavirus <sup>2</sup> (RV) RV1 (2-dose series); RV5 (3-dose series)                      |                      |                                  | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose             | See footnote 2                             |  |        |        |   |           |   |                      |  |                      |           |           |
| Diphtheria, tetanus, & acellular pertussis <sup>3</sup> (DTaP: <7 yrs)                    |                      |                                  | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose             | 3 <sup>rd</sup> dose                       |  |        |        | ←-----4 <sup>th</sup> dose-----→                                    |           |   | 5 <sup>th</sup> dose |  |                      |           |           |
| <i>Haemophilus influenzae</i> type b <sup>4</sup> (Hib)                                   |                      |                                  | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose             | See footnote 4                             |  |        |        | ←-----3 <sup>rd</sup> or 4 <sup>th</sup> dose, See footnote 4-----→ |           |   |                      |  |                      |           |           |
| Pneumococcal conjugate <sup>5</sup> (PCV13)   |                      |                                  | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose             | 3 <sup>rd</sup> dose                       |  |        |        | ←-----4 <sup>th</sup> dose-----→                                    |           |   |                      |  |                      |           |           |
| Inactivated poliovirus <sup>6</sup> (IPV: <18 yrs)  |                      |                                  | 1 <sup>st</sup> dose | 2 <sup>nd</sup> dose             | ←-----3 <sup>rd</sup> dose-----→           |  |        |        |   |           |   |                      | 4 <sup>th</sup> dose                         |                      |           |           |
| Influenza <sup>7</sup> (IIV; LAIV)  |                      |                                  |                      |                                  | Annual vaccination (IIV only) 1 or 2 doses |  |        |        |   |           | Annual vaccination (LAIV or IIV) 1 or 2 doses |                      | Annual vaccination (LAIV or IIV) 1 dose only |                      |           |           |
| Measles, mumps, rubella <sup>8</sup> (MMR)  |                      |                                  |                      |                                  | See footnote 8                             | ←-----1 <sup>st</sup> dose-----→           |        |        |   |           | 2 <sup>nd</sup> dose                          |                      |  |                      |           |           |
| Varicella <sup>9</sup> (VAR)  |                      |                                  |                      |                                  |  | ←-----1 <sup>st</sup> dose-----→           |        |        |   |           | 2 <sup>nd</sup> dose                          |                      |  |                      |           |           |
| Hepatitis A <sup>10</sup> (HepA)  |                      |                                  |                      |                                  |  | ←-----2-dose series, See footnote 10-----→ |        |        |   |           |   |                      |  |                      |           |           |
| Meningococcal <sup>11</sup> (Hib-MenCY ≥ 6 weeks; MenACWY-D ≥ 9 mos; MenACWY-CRM ≥ 2 mos) |                      |                                  | See footnote 11      |                                  |  |  |        |        |   |           |   |                      |  | 1 <sup>st</sup> dose |           | Booster   |
| Tetanus, diphtheria, & acellular pertussis <sup>12</sup> (Tdap: ≥7 yrs)                   |                      |                                  |                      |                                  |  |  |        |        |   |           |   |                      |  | (Tdap)               |           |           |
| Human papillomavirus <sup>13</sup> (2vHPV: females only; 4vHPV, 9vHPV: males and females) |                      |                                  |                      |                                  |  |  |        |        |   |           |   |                      |  | (3-dose series)      |           |           |
| Meningococcal B <sup>11</sup>   |                      |                                  |                      |                                  |  |  |        |        |   |           |   |                      | See footnote 11                              |                      |           |           |
| Pneumococcal polysaccharide <sup>5</sup> (PPSV23)   |                      |                                  |                      |                                  |  |  |        |        |   |           | See footnote 5                                |                      |  |                      |           |           |

Range of recommended ages for all children
  Range of recommended ages for catch-up immunization
  Range of recommended ages for certain high-risk groups
  Range of recommended ages for non-high-risk groups that may receive vaccine, subject to individual clinical decision making
  No recommendation

This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at <http://www.cdc.gov/vaccines/hcp/acip-recs/index.html>. Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online (<http://www.vaers.hhs.gov>) or by telephone (800-822-7967). Suspected cases of vaccine-preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online (<http://www.cdc.gov/vaccines/recs/vac-admin/contraindications.htm>) or by telephone (800-CDC-INFO [800-232-4636]).

This schedule is approved by the Advisory Committee on Immunization Practices (<http://www.cdc.gov/vaccines/acip>), the American Academy of Pediatrics (<http://www.aap.org>), the American Academy of Family Physicians (<http://www.aafp.org>), and the American College of Obstetricians and Gynecologists (<http://www.acog.org>).

**NOTE: The above recommendations must be read along with the footnotes of this schedule.**

**FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind —United States, 2016.**

The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. Always use this table in conjunction with Figure 1 and the footnotes that follow.

| Children age 4 months through 6 years  |                        |   |   |  |                       |
|--|------------------------|---|---|--|-----------------------|
| Vaccine  | Minimum Age for Dose 1 | Minimum Interval Between Doses  |   |  |                       |
|  |                        | Dose 1 to Dose 2  | Dose 2 to Dose 3  | Dose 3 to Dose 4   | Dose 4 to Dose 5      |
| Hepatitis B <sup>1</sup>   | Birth                  | 4 weeks   | 8 weeks<br>and at least 16 weeks after first dose.<br>Minimum age for the final dose is 24 weeks.   |  |                       |
| Rotavirus <sup>2</sup>   | 6 weeks                | 4 weeks   | 4 weeks <sup>2</sup>  |  |                       |
| Diphtheria, tetanus, and acellular pertussis <sup>2</sup>  | 6 weeks                | 4 weeks   | 4 weeks   | 6 months   | 6 months <sup>3</sup> |
| <i>Haemophilus influenzae</i> type b <sup>4</sup>  | 6 weeks                | 4 weeks<br>if first dose was administered before the 1 <sup>st</sup> birthday.<br>8 weeks (as final dose)<br>if first dose was administered at age 12 through 14 months.<br>No further doses needed if first dose was administered at age 15 months or older.   | 4 weeks <sup>4</sup><br>if current age is younger than 12 months <b>and</b> first dose was administered at younger than age 7 months, <b>and</b> at least 1 previous dose was PRP-T (ActHib, Pentacel) or unknown.<br>8 weeks<br>and age 12 through 59 months (as final dose) <sup>4</sup><br>• if current age is younger than 12 months <b>and</b> first dose was administered at age 7 through 11 months (wait until at least 12 months old);<br>OR<br>• if current age is 12 through 59 months <b>and</b> first dose was administered before the 1 <sup>st</sup> birthday, <b>and</b> second dose administered at younger than 15 months;<br>OR<br>• if both doses were PRP-OMP (PedvaxHIB; Comvax) <b>and</b> were administered before the 1 <sup>st</sup> birthday (wait until at least 12 months old).<br>No further doses needed<br>if previous dose was administered at age 15 months or older. | 8 weeks (as final dose)<br>This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 <sup>st</sup> birthday.  |                       |
| Pneumococcal <sup>5</sup>  | 6 weeks                | 4 weeks<br>if first dose administered before the 1 <sup>st</sup> birthday.<br>8 weeks (as final dose for healthy children)<br>if first dose was administered at the 1 <sup>st</sup> birthday or after.<br>No further doses needed<br>for healthy children if first dose administered at age 24 months or older. | 4 weeks<br>if current age is younger than 12 months and previous dose given at <7months old.<br>8 weeks (as final dose for healthy children)<br>if previous dose given between 7-11 months (wait until at least 12 months old);<br>OR<br>if current age is 12 months or older and at least 1 dose was given before age 12 months.<br>No further doses needed for healthy children if previous dose administered at age 24 months or older.  | 8 weeks (as final dose)<br>This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age. |                       |
| Inactivated poliovirus <sup>6</sup>  | 6 weeks                | 4 weeks <sup>6</sup>  | 4 weeks <sup>6</sup>  | 6 months <sup>6</sup> (minimum age 4 years for final dose).  |                       |
| Measles, mumps, rubella <sup>8</sup>   | 12 months              | 4 weeks   |   |  |                       |
| Varicella <sup>9</sup>   | 12 months              | 3 months  |   |  |                       |
| Hepatitis A <sup>10</sup>  | 12 months              | 6 months  |   |  |                       |
| Meningococcal <sup>11</sup><br>(Hib-MenCY ≥ 6 weeks;<br>MenACWY-D ≥ 9 mos;<br>MenACWY-CRM ≥ 2 mos) | 6 weeks                | 8 weeks <sup>11</sup>   | See footnote 11   | See footnote 11  |                       |
| Children and adolescents age 7 through 18 years  |                        |   |   |  |                       |
| Meningococcal <sup>11</sup><br>(Hib-MenCY ≥ 6 weeks;<br>MenACWY-D ≥ 9 mos;<br>MenACWY-CRM ≥ 2 mos) | Not Applicable (N/A)   | 8 weeks <sup>11</sup>   |   |  |                       |
| Tetanus, diphtheria, tetanus, diphtheria, and acellular pertussis <sup>12</sup>                    | 7 years <sup>12</sup>  | 4 weeks   | 4 weeks<br>if first dose of DTaP/DT was administered before the 1 <sup>st</sup> birthday.<br>6 months (as final dose)<br>if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 <sup>st</sup> birthday.   | 6 months if first dose of DTaP/DT was administered before the 1 <sup>st</sup> birthday.  |                       |
| Human papillomavirus <sup>13</sup>   | 9 years                | Routine dosing intervals are recommended. <sup>13</sup>   |   |  |                       |
| Hepatitis A <sup>10</sup>  | N/A                    | 6 months  |   |  |                       |
| Hepatitis B <sup>1</sup>   | N/A                    | 4 weeks   | 8 weeks <b>and</b> at least 16 weeks after first dose.  |  |                       |
| Inactivated poliovirus <sup>6</sup>  | N/A                    | 4 weeks   | 4 weeks <sup>6</sup>  | 6 months <sup>6</sup>  |                       |
| Measles, mumps, rubella <sup>8</sup>   | N/A                    | 4 weeks   |   |  |                       |
| Varicella <sup>9</sup>   | N/A                    | 3 months if younger than age 13 years.<br>4 weeks if age 13 years or older.   |   |  |                       |

**NOTE: The above recommendations must be read along with the footnotes of this schedule.**

# Footnotes — Recommended immunization schedule for persons aged 0 through 18 years—United States, 2016

For further guidance on the use of the vaccines mentioned below, see: <http://www.cdc.gov/vaccines/hcp/acip-recs/index.html>.

For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.

## Additional information

- For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at <http://www.cdc.gov/vaccines/hcp/acip-recs/index.html>.
- For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
- Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered  $\geq 5$  days earlier than the minimum interval or minimum age should not be counted as valid doses and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see *MMWR, General Recommendations on Immunization and Reports* / Vol. 60 / No. 2; Table 1. *Recommended and minimum ages and intervals between vaccine doses* available online at <http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf>.
- Information on travel vaccine requirements and recommendations is available at <http://wwwnc.cdc.gov/travel/destinations/list>.
- For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, "Vaccination of persons with primary and secondary immunodeficiencies," in *General Recommendations on Immunization (ACIP)*, available at <http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf>; and American Academy of Pediatrics. "Immunization in Special Clinical Circumstances," in Kimberlin DW, Brady MT, Jackson MA, Long SS eds. *Red Book: 2015 report of the Committee on Infectious Diseases*. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics.

## 1. Hepatitis B (HepB) vaccine. (Minimum age: birth)

### Routine vaccination:

#### At birth:

- Administer monovalent HepB vaccine to all newborns before hospital discharge.
- For infants born to hepatitis B surface antigen (HBsAg)-positive mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune globulin (HBIG) within 12 hours of birth. These infants should be tested for HBsAg and antibody to HBsAg (anti-HBs) at age 9 through 18 months (preferably at the next well-child visit) or 1 to 2 months after completion of the HepB series if the series was delayed; CDC recently recommended testing occur at age 9 through 12 months; see <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6439a6.htm>.
- If mother's HBsAg status is unknown, within 12 hours of birth administer HepB vaccine regardless of birth weight. For infants weighing less than 2,000 grams, administer HBIG in addition to HepB vaccine within 12 hours of birth. Determine mother's HBsAg status as soon as possible and, if mother is HBsAg-positive, also administer HBIG for infants weighing 2,000 grams or more as soon as possible, but no later than age 7 days.

### Doses following the birth dose:

- The second dose should be administered at age 1 or 2 months. Monovalent HepB vaccine should be used for doses administered before age 6 weeks.
- Infants who did not receive a birth dose should receive 3 doses of a HepB-containing vaccine on a schedule of 0, 1 to 2 months, and 6 months starting as soon as feasible. See Figure 2.
- Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks), administer the third dose at least 8 weeks after the second dose AND at least 16 weeks after the **first** dose. The final (third or fourth) dose in the HepB vaccine series should be administered **no earlier than age 24 weeks**.
- Administration of a total of 4 doses of HepB vaccine is permitted when a combination vaccine containing HepB is administered after the birth dose.

### Catch-up vaccination:

- Unvaccinated persons should complete a 3-dose series.
- A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for use in children aged 11 through 15 years.
- For other catch-up guidance, see Figure 2.

## 2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] and RV5 [RotaTeq])

### Routine vaccination:

Administer a series of RV vaccine to all infants as follows:

1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age.
2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months.
3. If any dose in the series was RotaTeq or vaccine product is unknown for any dose in the series, a total of 3 doses of RV vaccine should be administered.

### Catch-up vaccination:

- The maximum age for the first dose in the series is 14 weeks, 6 days; vaccination should not be initiated for infants aged 15 weeks, 0 days or older.
- The maximum age for the final dose in the series is 8 months, 0 days.
- For other catch-up guidance, see Figure 2.

## 3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. (Minimum age: 6 weeks. Exception: DTaP-IPV [Kinrix, Quadracel]: 4 years)

### Routine vaccination:

- Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 through 18 months, and 4 through 6 years. The fourth dose may be administered as early as age 12 months, provided at least 6 months have elapsed since the third dose.
- Inadvertent administration of 4th DTaP dose early: If the fourth dose of DTaP was administered at least 4 months, but less than 6 months, after the third dose of DTaP, it need not be repeated.

## 3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine (cont'd)

### Catch-up vaccination:

- The fifth dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.
- For other catch-up guidance, see Figure 2.

## 4. Haemophilus influenzae type b (Hib) conjugate vaccine. (Minimum age: 6 weeks for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-MenCY (MenHibrix)], PRP-OMP [PedvaxHIB or COMVAX], 12 months for PRP-T [Hiberix])

### Routine vaccination:

- Administer a 2- or 3-dose Hib vaccine primary series and a booster dose (dose 3 or 4 depending on vaccine used in primary series) at age 12 through 15 months to complete a full Hib vaccine series.
- The primary series with ActHib, MenHibrix, or Pentacel consists of 3 doses and should be administered at 2, 4, and 6 months of age. The primary series with PedvaxHib or COMVAX consists of 2 doses and should be administered at 2 and 4 months of age; a dose at age 6 months is not indicated.
- One booster dose (dose 3 or 4 depending on vaccine used in primary series) of any Hib vaccine should be administered at age 12 through 15 months. An exception is Hiberix vaccine. Hiberix should only be used for the booster (final) dose in children aged 12 months through 4 years who have received at least 1 prior dose of Hib-containing vaccine.
- For recommendations on the use of MenHibrix in patients at increased risk for meningococcal disease, please refer to the meningococcal vaccine footnotes and also to *MMWR* February 28, 2014 / 63(RR01);1-13, available at <http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf>.

### Catch-up vaccination:

- If dose 1 was administered at ages 12 through 14 months, administer a second (final) dose at least 8 weeks after dose 1, regardless of Hib vaccine used in the primary series.
- If both doses were PRP-OMP (PedvaxHIB or COMVAX), and were administered before the first birthday, the third (and final) dose should be administered at age 12 through 59 months and at least 8 weeks after the second dose.
- If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a third (and final) dose at age 12 through 15 months or 8 weeks after second dose, whichever is later.
- If first dose is administered before the first birthday and second dose administered at younger than 15 months, a third (and final) dose should be administered 8 weeks later.
- For unvaccinated children aged 15 months or older, administer only 1 dose.
- For other catch-up guidance, see Figure 2. For catch-up guidance related to MenHibrix, please see the meningococcal vaccine footnotes and also *MMWR* February 28, 2014 / 63(RR01);1-13, available at <http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf>.

### Vaccination of persons with high-risk conditions:

- Children aged 12 through 59 months who are at increased risk for Hib disease, including chemotherapy recipients and those with anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, immunoglobulin deficiency, or early component complement deficiency, who have received either no doses or only 1 dose of Hib vaccine before 12 months of age, should receive 2 additional doses of Hib vaccine 8 weeks apart; children who received 2 or more doses of Hib vaccine before 12 months of age should receive 1 additional dose.
- For patients younger than 5 years of age undergoing chemotherapy or radiation treatment who received a Hib vaccine dose(s) within 14 days of starting therapy or during therapy, repeat the dose(s) at least 3 months following therapy completion.
- Recipients of hematopoietic stem cell transplant (HSCT) should be revaccinated with a 3-dose regimen of Hib vaccine starting 6 to 12 months after successful transplant, regardless of vaccination history; doses should be administered at least 4 weeks apart.
- A single dose of any Hib-containing vaccine should be administered to unimmunized\* children and adolescents 15 months of age and older undergoing an elective splenectomy; if possible, vaccine should be administered at least 14 days before procedure.

For further guidance on the use of the vaccines mentioned below, see: <http://www.cdc.gov/vaccines/hcp/acip-recs/index.html>.

**4. *Haemophilus influenzae* type b (Hib) conjugate vaccine (cont'd)**

- Hib vaccine is not routinely recommended for patients 5 years or older. However, 1 dose of Hib vaccine should be administered to unimmunized\* persons aged 5 years or older who have anatomic or functional asplenia (including sickle cell disease) and unvaccinated persons 5 through 18 years of age with HIV infection.

\*Patients who have not received a primary series and booster dose or at least 1 dose of Hib vaccine after 14 months of age are considered unimmunized.

**5. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years for PPSV23)**

**Routine vaccination with PCV13:**

- Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 months and at age 12 through 15 months.
- For children aged 14 through 59 months who have received an age-appropriate series of 7-valent PCV (PCV7), administer a single supplemental dose of 13-valent PCV (PCV13).

**Catch-up vaccination with PCV13:**

- Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.
- For other catch-up guidance, see Figure 2.

**Vaccination of persons with high-risk conditions with PCV13 and PPSV23:**

- All recommended PCV13 doses should be administered prior to PPSV23 vaccination if possible.
- For children 2 through 5 years of age with any of the following conditions: chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy); diabetes mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; solid organ transplantation; or congenital immunodeficiency:

1. Administer 1 dose of PCV13 if any incomplete schedule of 3 doses of PCV (PCV7 and/or PCV13) were received previously.
2. Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated or any incomplete schedule of fewer than 3 doses of PCV (PCV7 and/or PCV13) were received previously.
3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other age-appropriate complete PCV7 series was received previously.
4. The minimum interval between doses of PCV (PCV7 or PCV13) is 8 weeks.
5. For children with no history of PPSV23 vaccination, administer PPSV23 at least 8 weeks after the most recent dose of PCV13.

- For children aged 6 through 18 years who have cerebrospinal fluid leak; cochlear implant; sickle cell disease and other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma:

1. If neither PCV13 nor PPSV23 has been received previously, administer 1 dose of PCV13 now and 1 dose of PPSV23 at least 8 weeks later.
2. If PCV13 has been received previously but PPSV23 has not, administer 1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, administer 1 dose of PCV13 at least 8 weeks after the most recent dose of PPSV23.

- For children aged 6 through 18 years with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure), chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver disease, who have not received PPSV23, administer 1 dose of PPSV23. If PCV13 has been received previously, then PPSV23 should be administered at least 8 weeks after any prior PCV13 dose.

- A single revaccination with PPSV23 should be administered 5 years after the first dose to children with sickle cell disease or other hemoglobinopathies; anatomic or functional asplenia; congenital or acquired immunodeficiencies; HIV infection; chronic renal failure; nephrotic syndrome; diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized malignancy; solid organ transplantation; or multiple myeloma.

**6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)**

**Routine vaccination:**

- Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 through 6 years. The final dose in the series should be administered on or after the fourth birthday and at least 6 months after the previous dose.

**Catch-up vaccination:**

- In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk of imminent exposure to circulating poliovirus (i.e., travel to a polio-endemic region or during an outbreak).
- If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years and at least 6 months after the previous dose.
- A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose.

**6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks) (cont'd)**

- If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age. If only OPV were administered, and all doses were given prior to 4 years of age, one dose of IPV should be given at 4 years or older, at least 4 weeks after the last OPV dose.
- IPV is not routinely recommended for U.S. residents aged 18 years or older.
- For other catch-up guidance, see Figure 2.

**7. Influenza vaccines. (Minimum age: 6 months for inactivated influenza vaccine [IIV], 2 years for live, attenuated influenza vaccine [LAIV])**

**Routine vaccination:**

- Administer influenza vaccine annually to all children beginning at age 6 months. For most healthy, nonpregnant persons aged 2 through 49 years, either LAIV or IIV may be used. However, LAIV should NOT be administered to some persons, including 1) persons who have experienced severe allergic reactions to LAIV, any of its components, or to a previous dose of any other influenza vaccine; 2) children 2 through 17 years receiving aspirin or aspirin-containing products; 3) persons who are allergic to eggs; 4) pregnant women; 5) immunosuppressed persons; 6) children 2 through 4 years of age with asthma or who had wheezing in the past 12 months; or 7) persons who have taken influenza antiviral medications in the previous 48 hours. For all other contraindications and precautions to use of LAIV, see *MMWR* August 7, 2015 / 64(30):818-25 available at <http://www.cdc.gov/mmwr/pdf/wk/mm6430.pdf>.

**For children aged 6 months through 8 years:**

- For the 2015-16 season, administer 2 doses (separated by at least 4 weeks) to children who are receiving influenza vaccine for the first time. Some children in this age group who have been vaccinated previously will also need 2 doses. For additional guidance, follow dosing guidelines in the 2015-16 ACIP influenza vaccine recommendations, *MMWR* August 7, 2015 / 64(30):818-25, available at <http://www.cdc.gov/mmwr/pdf/wk/mm6430.pdf>.
- For the 2016-17 season, follow dosing guidelines in the 2016 ACIP influenza vaccine recommendations.

**For persons aged 9 years and older:**

- Administer 1 dose.

**8. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 months for routine vaccination)**

**Routine vaccination:**

- Administer a 2-dose series of MMR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 4 weeks have elapsed since the first dose.
- Administer 1 dose of MMR vaccine to infants aged 6 through 11 months before departure from the United States for international travel. These children should be revaccinated with 2 doses of MMR vaccine, the first at age 12 through 15 months (12 months if the child remains in an area where disease risk is high), and the second dose at least 4 weeks later.
- Administer 2 doses of MMR vaccine to children aged 12 months and older before departure from the United States for international travel. The first dose should be administered on or after age 12 months and the second dose at least 4 weeks later.

**Catch-up vaccination:**

- Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.

**9. Varicella (VAR) vaccine. (Minimum age: 12 months)**

**Routine vaccination:**

- Administer a 2-dose series of VAR vaccine at ages 12 through 15 months and 4 through 6 years. The second dose may be administered before age 4 years, provided at least 3 months have elapsed since the first dose. If the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid.

**Catch-up vaccination:**

- Ensure that all persons aged 7 through 18 years without evidence of immunity (see *MMWR* 2007 / 56 [No. RR-4], available at <http://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf>) have 2 doses of varicella vaccine. For children aged 7 through 12 years, the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is 4 weeks.

**10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)**

**Routine vaccination:**

- Initiate the 2-dose HepA vaccine series at 12 through 23 months; separate the 2 doses by 6 to 18 months.
- Children who have received 1 dose of HepA vaccine before age 24 months should receive a second dose 6 to 18 months after the first dose.
- For any person aged 2 years and older who has not already received the HepA vaccine series, 2 doses of HepA vaccine separated by 6 to 18 months may be administered if immunity against hepatitis A virus infection is desired.

**Catch-up vaccination:**

- The minimum interval between the 2 doses is 6 months.

For further guidance on the use of the vaccines mentioned below, see: <http://www.cdc.gov/vaccines/hcp/acip-recs/index.html>.

#### 10. Hepatitis A (HepA) vaccine (cont'd)

##### Special populations:

- Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection. This includes persons traveling to or working in countries that have high or intermediate endemicity of infection; men having sex with men; users of injection and non-injection illicit drugs; persons who work with HAV-infected primates or with HAV in a research laboratory; persons with clotting-factor disorders; persons with chronic liver disease; and persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from a country with high or intermediate endemicity. The first dose should be administered as soon as the adoption is planned, ideally 2 or more weeks before the arrival of the adoptee.

#### 11. Meningococcal vaccines. (Minimum age: 6 weeks for Hib-MenCY [MenHibrix], 9 months for MenACWY-D [Menactra], 2 months for MenACWY-CRM [Menveo], 10 years for serogroup B meningococcal [MenB] vaccines: MenB-4C [Bexsero] and MenB-FHbp [Trumenba])

##### Routine vaccination:

- Administer a single dose of Menactra or Menveo vaccine at age 11 through 12 years, with a booster dose at age 16 years.
- Adolescents aged 11 through 18 years with human immunodeficiency virus (HIV) infection should receive a 2-dose primary series of Menactra or Menveo with at least 8 weeks between doses.
- For children aged 2 months through 18 years with high-risk conditions, see below.

##### Catch-up vaccination:

- Administer Menactra or Menveo vaccine at age 13 through 18 years if not previously vaccinated.
- If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses.
- If the first dose is administered at age 16 years or older, a booster dose is not needed.
- For other catch-up guidance, see Figure 2.

##### Clinical discretion:

- Young adults aged 16 through 23 years (preferred age range is 16 through 18 years) may be vaccinated with either a 2-dose series of Bexsero or a 3-dose series of Trumenba vaccine to provide short-term protection against most strains of serogroup B meningococcal disease. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.

##### Vaccination of persons with high-risk conditions and other persons at increased risk of disease:

##### Children with anatomic or functional asplenia (including sickle cell disease):

##### Meningococcal conjugate ACWY vaccines:

1. Menveo
  - o Children who initiate vaccination at 8 weeks: Administer doses at 2, 4, 6, and 12 months of age.
  - o Unvaccinated children who initiate vaccination at 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks after the first dose AND after the first birthday.
  - o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart.
2. MenHibrix
  - o Children who initiate vaccination at 6 weeks: Administer doses at 2, 4, 6, and 12 through 15 months of age.
  - o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.
3. Menactra
  - o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart. If Menactra is administered to a child with asplenia (including sickle cell disease), do not administer Menactra until 2 years of age and at least 4 weeks after the completion of all PCV13 doses.

##### Meningococcal B vaccines:

1. Bexsero or Trumenba
  - o Persons 10 years or older who have not received a complete series: Administer a 2-dose series of Bexsero, at least 1 month apart. Or a 3-dose series of Trumenba, with the second dose at least 2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.

##### Children with persistent complement deficiency (includes persons with inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab (Soliris®):

##### Meningococcal conjugate ACWY vaccines:

1. Menveo
  - o Children who initiate vaccination at 8 weeks: Administer doses at 2, 4, 6, and 12 months of age.
  - o Unvaccinated children who initiate vaccination at 7 through 23 months: Administer 2 doses, with the second dose at least 12 weeks after the first dose AND after the first birthday.
  - o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart.
2. MenHibrix
  - o Children who initiate vaccination 6 weeks: Administer doses at 2, 4, 6, and 12 through 15 months of age.
  - o If the first dose of MenHibrix is given at or after 12 months of age, a total of 2 doses should be given at least 8 weeks apart to ensure protection against serogroups C and Y meningococcal disease.

#### 11. Meningococcal vaccines (cont'd)

##### 3. Menactra

- o Children 9 through 23 months: Administer 2 primary doses at least 12 weeks apart.
- o Children 24 months and older who have not received a complete series: Administer 2 primary doses at least 8 weeks apart.

##### Meningococcal B vaccines:

##### 1. Bexsero or Trumenba

- o Persons 10 years or older who have not received a complete series: Administer a 2-dose series of Bexsero, at least 1 month apart. Or a 3-dose series of Trumenba, with the second dose at least 2 months after the first and the third dose at least 6 months after the first. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.

##### For children who travel to or reside in countries in which meningococcal disease is hyperendemic or epidemic, including countries in the African meningitis belt or the Hajj

- administer an age-appropriate formulation and series of Menactra or Menveo for protection against serogroups A and W meningococcal disease. Prior receipt of MenHibrix is not sufficient for children traveling to the meningitis belt or the Hajj because it does not contain serogroups A or W.

##### For children at risk during a community outbreak attributable to a vaccine serogroup

- administer or complete an age- and formulation-appropriate series of MenHibrix, Menactra, or Menveo, Bexsero or Trumenba.

For booster doses among persons with high-risk conditions, refer to *MMWR* 2013 / 62(RR02);1-22, available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm>.

For other catch-up recommendations for these persons, and complete information on use of meningococcal vaccines, including guidance related to vaccination of persons at increased risk of infection, see *MMWR* March 22, 2013 / 62(RR02);1-22, and *MMWR* October 23, 2015 / 64(41); 1171-1176 available at <http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf>, and <http://www.cdc.gov/mmwr/pdf/wk/mm6441.pdf>.

#### 12. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. (Minimum age: 10 years for both Boostrix and Adacel)

##### Routine vaccination:

- Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 12 years.
- Tdap may be administered regardless of the interval since the last tetanus and diphtheria toxoid-containing vaccine.
- Administer 1 dose of Tdap vaccine to pregnant adolescents during each pregnancy (preferred during 27 through 36 weeks gestation) regardless of time since prior Td or Tdap vaccination.

##### Catch-up vaccination:

- Persons aged 7 years and older who are not fully immunized with DTaP vaccine should receive Tdap vaccine as 1 (preferably the first) dose in the catch-up series; if additional doses are needed, use Td vaccine. For children 7 through 10 years who receive a dose of Tdap as part of the catch-up series, an adolescent Tdap vaccine dose at age 11 through 12 years should NOT be administered. Td should be administered instead 10 years after the Tdap dose.
- Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter.
- Inadvertent doses of DTaP vaccine:
  - If administered inadvertently to a child aged 7 through 10 years may count as part of the catch-up series. This dose may count as the adolescent Tdap dose, or the child can later receive a Tdap booster dose at age 11 through 12 years.
  - If administered inadvertently to an adolescent aged 11 through 18 years, the dose should be counted as the adolescent Tdap booster.
- For other catch-up guidance, see Figure 2.

#### 13. Human papillomavirus (HPV) vaccines. (Minimum age: 9 years for 2vHPV [Cervarix], 4vHPV [Gardasil] and 9vHPV [Gardasil 9])

##### Routine vaccination:

- Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 6 months to all adolescents aged 11 through 12 years. 9vHPV, 4vHPV or 2vHPV may be used for females, and only 9vHPV or 4vHPV may be used for males.
- The vaccine series may be started at age 9 years.
- Administer the second dose 1 to 2 months after the first dose (minimum interval of 4 weeks); administer the third dose 16 weeks after the second dose (minimum interval of 12 weeks) and 24 weeks after the first dose.
- Administer HPV vaccine beginning at age 9 years to children and youth with any history of sexual abuse or assault who have not initiated or completed the 3-dose series.

##### Catch-up vaccination:

- Administer the vaccine series to females (2vHPV or 4vHPV or 9vHPV) and males (4vHPV or 9vHPV) at age 13 through 18 years if not previously vaccinated.
- Use recommended routine dosing intervals (see Routine vaccination above) for vaccine series catch-up.

# Meningococcal Vaccination Recommendations by Age and/or Risk Factor for Serogroups A, C, W, or Y Protection

A separate vaccine is needed for protection against meningococcal serogroup B disease.

**MenACWY** = Menactra (sanofi) and Menveo (Novartis)  
**MenACWY-D** = Menactra      **Hib-MenCY** = MenHibrix (GlaxoSmithKline)  
**MenACWY-CRM** = Menveo      **MPSV** = Menomune (sanofi)

| Routine Recommendations for Quadrivalent Meningococcal Conjugate Vaccine (MenACWY)  |   |
|---|---|
| For preteens age 11 through 12 years  | Give dose #1 of 2-dose MenACWY series. <sup>1</sup> (Dose #2 will be due at age 16 years.)  |
| For teens age 13 through 15 years   | Give catch-up dose #1 of 2-dose MenACWY series. (Dose #2 will be due at age 16 years.)  |
| For teens age 16 through 18 years   | Give dose #2 of MenACWY. Separate from dose #1 by at least 8 weeks.   |
| Catch-up for teens age 16 through 18 years  | If no history of prior vaccination with MenACWY, give 1 dose of MenACWY.  |
| For first year college students, age 19 through 21 years, living in residence halls | If no history of prior vaccination with MenACWY, give 1 dose of MenACWY. <sup>1</sup> If history of 1 dose of MenACWY given when younger than age 16 years, give dose #2 of MenACWY. <sup>2</sup> |

| Risk-based Recommendations for Persons with Underlying Medical Conditions or Other Risk Factors  |   |  |
|--|---|--|
| Targeted group by age and/or risk factor   | Primary dose(s)   | Booster dose(s)  |
| Travelers to or residents of countries where meningococcal disease is hyperendemic or epidemic, <sup>3</sup> people present during outbreaks caused by a vaccine serogroup, <sup>4</sup> and other people with prolonged increased risk for exposure (e.g., microbiologists routinely working with <i>Neisseria meningitidis</i> ) |   |  |
| For children age 2 through 18 months   | Give MenACWY-CRM at ages 2, 4, 6 and 12-15 months <sup>5</sup>  | If risk continues, give initial booster after 3 years followed by boosters every 5 years |
| For children age 7 through 23 months who have not initiated a series of MenACWY-CRM or Hib-MenCY   | Give 2 doses, separated by 3 months, <sup>6</sup> of MenACWY-CRM (if age 7-23 months) <sup>7</sup> or MenACWY-D (if age 9-23 months)  |  |
| For age 2 through 55 years   | Give 1 dose of MenACWY. <sup>1</sup>  | Boost every 5 years with MenACWY. <sup>8,9</sup>   |
| For ages 56 years and older  | If no previous MenACWY dose and either short-term travel or outbreak-related, give 1 dose of MPSV; all others, give 1 dose of MenACWY | Boost every 5 years with MenACWY. <sup>9</sup>   |
| <b>People with persistent complement component deficiencies<sup>10</sup></b>   |   |  |
| For age 2 through 18 months  | Give MenACWY-CRM or Hib-MenCY at ages 2, 4, 6 and 12-15 months.   | Give MenACWY booster after 3 years followed by boosters every 5 years thereafter.        |
| For children age 7 through 23 months who have not initiated a series of MenACWY-CRM or Hib-MenCY   | Give 2 doses, separated by 3 months, of MenACWY-CRM (if age 7-23 months) <sup>7</sup> or MenACWY-D (if age 9-23 months).              |  |
| For ages 2 through 55 years  | Give 2 doses of MenACWY, 2 months apart.  | Boost every 5 years with MenACWY. <sup>8,11</sup>  |
| For age 56 years and older   | Give 2 doses of MenACWY, 2 months apart.  | Boost every 5 years with MenACWY. <sup>11</sup>  |
| <b>People with functional or anatomic asplenia, including sickle cell disease</b>  |   |  |
| For age 2 through 18 months  | Give MenACWY-CRM or Hib-MenCY at ages 2, 4, 6 and 12-15 months.   | Give MenACWY booster after 3 years followed by boosters every 5 years thereafter.        |
| For children age 19 through 23 months who have not initiated a series of MenACWY-CRM or HibMenCY   | Give 2 doses of MenACWY-CRM, 3 months apart.  |  |
| For ages 2 through 55 years  | Give 2 doses of MenACWY, 2 months apart. <sup>12</sup>  | Boost every 5 years with MenACWY. <sup>8,11</sup>  |
| For ages 56 years and older  | Give 2 doses of MenACWY, 2 months apart.  | Boost every 5 years with MenACWY. <sup>11</sup>  |

## FOOTNOTES

1. If the person is HIV-positive, give 2 doses, 2 months apart.
2. The minimum interval between doses of MenACWY is 8 weeks.
3. Prior receipt of Hib-MenCY is not sufficient for children traveling to the Hajj or African meningitis belt as it doesn't provide protection against serogroups A or W.
4. Seek advice of local public health authorities to determine if vaccination is recommended.
5. Children age 2 through 18 months who are present during outbreaks caused by serogroups C or Y may be given an age-appropriate series of Hib-MenCY.
6. If a child age 7 through 23 months will enter an endemic area in less than 3 months, give doses as close as 2 months apart.
7. If using MenACWY-CRM, dose 2 should be given no younger than age 12 months.
8. If primary dose(s) given when younger than age 7 years, give initial booster after 3 years, followed by boosters every 5 years.
9. Booster doses are recommended if the person remains at increased risk.
10. Persistent complement component deficiencies include C3, C5-C9, properdin, factor H, and factor D.
11. If the person received a 1-dose primary series, give booster at the earliest opportunity, then boost every 5 years.
12. Children with functional or anatomic asplenia should complete an age-appropriate series of PCV13 vaccine before vaccination with MenACWY-D; MenACWY-D should be given at least 4 weeks following last dose of PCV13. MenACWY-CRM or Hib-MenCY may be given at any time before or after PCV13.

# Immunization Best Practices

## 1. Vaccinate staff.

Vaccinate all personnel who have contact with patients with all recommended vaccines.

## 2. Assess at every visit.

Decrease missed opportunities by reviewing immunization status at **all** types of visits (e.g., acute care and well child) and administering **all** vaccines indicated.

## 3. Make a strong recommendation for all indicated immunizations.

- Studies show that providers who strongly recommend all vaccines equally have very high acceptance rates. This is particularly important for improving HPV vaccine acceptance.
- For parents or patients with vaccine hesitancy, reinforce that immunizations are very safe and very important. Be prepared to take time to answer questions.

## 4. Schedule optimally.

- Hepatitis B: Give first dose at birth.
- Give any dose of vaccine not given at the recommended age at any following visit when indicated and feasible.
- Schedule immunizations prior to the maximum ACIP recommended age to ensure that children have received all of the recommended antigens by age 24 months.
- No research indicates “alternative schedules” or delaying vaccines is safer than the recommended schedule. Experts agree the best time to give immunizations to ensure infants are protected is as soon as possible. For help talking to parents about vaccine concerns, see this article by Ari Brown, MD: [www.immunize.org/catg.d/p2068.pdf](http://www.immunize.org/catg.d/p2068.pdf), or CDC’s website: [www.cdc.gov/vaccines/hcp/patient-ed/conversations/index.html](http://www.cdc.gov/vaccines/hcp/patient-ed/conversations/index.html)

## 5. Adhere to correct intervals and ages.

(a) Minimum intervals:

- Do **not** give vaccines before the recommended minimum age or interval for that antigen.
- Consider doses administered before the minimum age and/or minimum interval invalid.
- If an invalid dose has been given, count from the last (invalid) dose in order to determine when to give the next **valid** dose.

(b) Maximum intervals:

- There are no maximum intervals; it is **not** necessary to restart the series of any vaccine due to extended intervals between doses.

## 6. Follow only true contraindications.

Do not defer vaccination for children who present with a mild acute illness, with or without fever. Follow only true contraindications as outlined by the ACIP.

## 7. Use Vaccine Information Statements (VIS).

Provide patient, parent, or legal representative with a copy of the VIS with **each** dose of vaccine administered, and answer questions regarding vaccine risks and benefits. It is the provider’s responsibility to maintain copies of the most up-to-date VISs in their office. Subscribe to CDC’s e-mail update for VISs at [www.cdc.gov/vaccines/hcp/vis/index.html](http://www.cdc.gov/vaccines/hcp/vis/index.html), click on “Get E-Mail Updates,” and enter your e-mail address.

## 8. Educate yourself, staff, patients, and parents.

- Be familiar with reliable sources of evidence-based information about vaccines, vaccine safety, vaccine hesitancy and risk communication (see links below).
- Have a system for sharing this information with staff, patients and parents.

## 9. Document.

- Document in the patient’s record the date a patient moves or goes elsewhere for care (MOGE).
- Document chickenpox disease on the immunization record.
- Document contraindications to vaccines.
- Document parent refusal or deferral of any vaccine.
- Provide the patient or parent/legal guardian with an immunization card documenting the vaccines given and the date the next doses are due.

## 10. Carry out reminder/recall.

- Identify children who are due or overdue for immunizations (e.g., MIIS, EHR, computer billing system, other electronic tracking systems, tickler system, stickers on charts).
- Send out reminder or recall notices **at least twice a year**.
- Verify patient’s address and telephone number at each encounter; obtain a second contact number for back-up.

## 11. Develop a systematic approach.

- Designate an *Immunization Coordinator* to coordinate and monitor all immunization activities. The *Immunization Coordinator* keeps current with information about immunization, and communicates current schedules, guidelines, and policies to all staff.
- Have all providers in a practice formally agree to adhere to a common immunization schedule (based on ACIP guidelines).
- Post agreed upon common schedule throughout the practice.

## 12. Follow appropriate procedures for vaccine storage and handling.

- Formally designate one staff member to monitor vaccine ordering, receiving and storage.
- Consult the MDPH document *Guidelines for Compliance with Federal and State Vaccine Administration Requirements* for detailed instructions on proper vaccine storage and handling.
- Maintain up-to-date, written protocols for vaccine storage and handling procedures and share with all staff who handle vaccine.

## 13. Report adverse events.

Report clinically significant adverse events that follow immunization to the Vaccine Adverse Event Reporting System (VAERS). Find guidance on obtaining and completing a VAERS form at: [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by calling 1-800-822-7967.

## 14. Report cases.

Report suspect cases of vaccine-preventable diseases to your local board of health and to the MDPH Immunization Program, 617-983-6800 or toll free 888-658-2850. For information regarding disease reporting and control measures see the *Guide to Surveillance and Reporting* ([www.mass.gov/dph/epi](http://www.mass.gov/dph/epi)).

### Resources:

Massachusetts Department of Public Health (DPH): [www.mass.gov/dph/imm](http://www.mass.gov/dph/imm), 888-658-2850 or 617-983-6800

National Immunization Information Hotline: 1-800-232-4636 (1-800-CDC-INFO) and 1-888-232-6348 (TTY)

National Immunization Program: [www.cdc.gov/vaccines](http://www.cdc.gov/vaccines) Immunization Action Coalition: [www.immunize.org](http://www.immunize.org)

Children’s Hospital of Philadelphia Vaccine Education Center: [www.chop.edu/service/vaccine-education-center](http://www.chop.edu/service/vaccine-education-center)

American Academy of Pediatrics: [www.aap.org](http://www.aap.org)

## Massachusetts School Immunization Requirements for School Year 2016-2017\*

|  | Child Care/Preschool <sup>1</sup> | Kindergarten     | Grades 1-6   | Grades 7-12  | College <sup>2</sup>  |
|--|-----------------------------------|------------------|--|--|---|
| <b>Hepatitis B<sup>3</sup></b>         | 3 doses                           | 3 doses          | 3 doses  | 3 doses  | 3 doses for all health science students and full-time undergraduate and graduate students     |
| <b>DTaP/DTP/DT/Td/Tdap<sup>4</sup></b> | ≥4 doses DTaP/DTP                 | 5 doses DTaP/DTP | ≥4 doses DTaP/DTP or ≥3 doses Td   | 4 doses DTaP/DTP or ≥3 doses Td;<br>Plus 1 dose Tdap       | 1 dose Tdap for all health science students and full-time undergraduate and graduate students |
| <b>Polio<sup>5</sup></b>               | ≥3 doses                          | 4 doses          | ≥3 doses   | ≥3 doses   | NA  |
| <b>Hib<sup>6</sup></b>                 | 1 to 4 doses <sup>6</sup>         | NA               | NA   | NA   | NA  |
| <b>MMR<sup>7</sup></b>                 | 1 dose                            | 2 doses          | Grades 1-5: 2 doses<br>Grade 6: 2 doses measles, 1 mumps, 1 rubella<br>(See Phase-In Schedule) | 2 doses  | 2 doses for all health science students and full-time undergraduate and graduate students     |
| <b>Varicella<sup>8</sup></b>           | 1 dose                            | 2 doses          | Grades 1-5: 2 doses<br>Grade 6: 1 dose<br>(See Phase-In Schedule)                              | 2 doses  | 2 doses for all health science students and full-time undergraduate and graduate students     |
| <b>Meningococcal<sup>9,10</sup></b>    | NA                                | NA               | NA <sup>10</sup>   | 1 dose for new full-time residential students <sup>9</sup> | 1 dose for full-time residential students <sup>9</sup>  |

\*These requirements also apply to all new “enterers.” NA = no vaccine requirement for the grades indicated.

<sup>1</sup>**Child Care/Preschool:** Minimum requirements by 24 months; immunize younger children according to their age.

<sup>2</sup>**College:** Requirements apply to: 1) all full-time undergraduate and graduate students; 2) all full-time and part-time health science students; and 3) any full-time or part-time student attending any postsecondary institution while on a student or other visa, including foreign students attending or visiting classes as part of a formal academic visitation or exchange program.

<sup>3</sup>**Hepatitis B:** 3 doses required for child care attendance and preschool entry, kindergarten-12<sup>th</sup> grade, and college (see footnote 2 above). Laboratory proof of immunity is acceptable.

<sup>4</sup>**DTaP/DTP/DT/Td/Tdap:** ≥4 doses required for child care attendance and preschool entry; 5 doses of DTaP/DTP required for school entry unless the 4th dose is given on or after the 4th birthday. DT is only acceptable with a letter stating a medical contraindication to DTaP/DTP. **One dose of Tdap is required for all students entering grade 7-12, full-time college freshmen-graduates and all health science students.** If it has been <5 years since the last dose of DTaP/DTP/DT/Td, Tdap is not required but is recommended regardless of the interval since the last tetanus-containing vaccine.

<sup>5</sup>**Polio:** ≥3 doses required for child care attendance and entry into preschool. 4 doses required for school entry, unless the 3rd dose is given on or after the 4th birthday, and ≥6 months following the previous dose, in which case only 3 doses are needed. Administer the final dose in the series on or after the 4th birthday and ≥6 months following the previous dose. If 4 doses are administered before age 4 years, a 5th dose is recommended at age 4-6 years.

<sup>6</sup>**Hib:** Required for child care attendance and preschool entry. The number of doses is determined by vaccine product and age the series begins.

<sup>7</sup>**MMR:** 1 dose of MMR is required for child care attendance and preschool entry; **2 doses are required for kindergarten-grade 5, grade 7-12, full-time undergraduate and graduate students and all health science students.** Laboratory proof of immunity is acceptable. **For college students, except health science students, birth before 1957 in the U.S. is also acceptable.** See Phase-In Schedule below.

<sup>8</sup>**Varicella:** 1 dose required for child care attendance and preschool entry; **2 doses required for kindergarten-grade 5, grade 7-12, full-time undergraduate and graduate students and all health science students, unless they have a reliable history of chickenpox.** A reliable history includes a diagnosis of chickenpox, or interpretation of parent/guardian description of chickenpox, by a physician, nurse practitioner, physician assistant or designee; or 2) laboratory proof of immunity. **Birth before 1980 in U.S. is acceptable for college students, except health science students.** See Phase-In Schedule below.

<sup>9</sup>**Meningococcal:** 1 dose MenACWY (formerly MCV4), or a dose of MPSV4 in the last 5 years, is required for 1) newly enrolled full-time students attending a secondary school with grades 9-12 (in ungraded classrooms, those with students ≥13 years) who will live in a dormitory or comparable congregate living arrangement approved by the secondary school; and 2) newly enrolled full-time undergraduate and graduate students in a degree program at a postsecondary institution (e.g., college) who will live in a dormitory or comparable congregate living arrangement approved by the institution. Students may decline the vaccine after they have read and signed the MDPH Meningococcal Information and Waiver Form provided by their institution. These requirements apply to newly-enrolled full-time residential students, regardless of grade and year of study.

<sup>10</sup>**At residential schools with lower grades:** The requirements apply to residential students in grades pre-K through 8 only if the school combines these grades in the same school with students in grades 9-12.

### Phase-In Schedule for MMR, Varicella, and Tdap Vaccines 2016-2017

|                              | 2016  | 2017   |
|------------------------------|---|--|
| <b>2 MMR and 2 Varicella</b> | K-5 and 7-12<br>College: full-time freshmen-graduates; all health science | K-12<br>College: full-time freshmen-graduates; all health science        |
| <b>Tdap</b>                  | Grades 7-12<br>College: full-time freshmen-graduates; all health science  | Grades 7-12<br>College: full-time freshmen-graduates; all health science |